Rani Therapeutics (RANI) Projected to Release Quarterly Earnings on Thursday

Rani Therapeutics (NASDAQ:RANI) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $0.9250 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI) last issued its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $1.12 million. On average, analysts expect Rani Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Rani Therapeutics Trading Up 3.0%

NASDAQ RANI opened at $0.84 on Thursday. The company’s 50-day moving average price is $0.80 and its 200-day moving average price is $1.02. The stock has a market cap of $104.54 million, a PE ratio of -2.06 and a beta of 0.78. Rani Therapeutics has a 12 month low of $0.44 and a 12 month high of $3.87.

Insider Buying and Selling

In other Rani Therapeutics news, CEO Talat Imran bought 35,000 shares of the business’s stock in a transaction on Friday, July 17th. The shares were acquired at an average price of $0.72 per share, with a total value of $25,200.00. Following the transaction, the chief executive officer owned 469,736 shares of the company’s stock, valued at approximately $338,209.92. This trade represents a 8.05% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 26.73% of the company’s stock.

Hedge Funds Weigh In On Rani Therapeutics

Institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Rani Therapeutics during the fourth quarter worth $69,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Rani Therapeutics in the 4th quarter valued at $93,000. Farallon Capital Management LLC bought a new position in shares of Rani Therapeutics in the 4th quarter worth $105,000. Kestra Private Wealth Services LLC lifted its stake in shares of Rani Therapeutics by 44.8% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company’s stock worth $113,000 after purchasing an additional 70,002 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Rani Therapeutics during the 4th quarter worth $155,000. 30.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RANI has been the subject of several research reports. Lake Street Capital began coverage on shares of Rani Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $9.00 price objective for the company. Wall Street Zen raised shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Weiss Ratings downgraded shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $5.00 price target on shares of Rani Therapeutics in a report on Wednesday, May 20th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Rani Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.75.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.